Aripiprazole Tablet
Product Images NDC 65862-665

Product Visual Gallery

This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 65862-665). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1: The Effects Of Other Drugs On Aripiprazole Pharmacokinetics (Aripiprazole Fig1)

This is a table presenting the effects of other drugs on Aripiprazole pharmacokinetics. The drugs listed include ketoconazole, quinidine, carbamazepine, famotidine, valproate, and lorazepam. The table shows the fold change and 90% confidence interval for Aripiprazole, as well as the change relative to the reference without an interacting drug. AUC (area under the curve) and Cmax (maximum concentration) are also presented.*

FDA Label Image

Package Label-principal Display Panel (5 mg Blister Carton (10 x 10) Unit-dose Tablets)

This is a medication description for Aripiprazole Tablets USP which contain 5 mg of the active ingredient. The package includes a Medication Guide to be given to each patient by the pharmacist. The indications and dosage information should be consulted from the accompanying package insert. The medication should be stored in tightly closed containers at room temperature. The product is distributed by Aurobindo Pharma USA, Inc. from their New Jersey location. The country of origin is India with a manufacturing date noted as "TS/DRUGS22/2009". There is also some printing and dotted lines that are not relevant for this description.*

FDA Label Image

Package Label-principal Display Panel (10 mg (30 Tablets Bottle))

This is a description of Aripiprazole Tablets, a prescription medication used to treat mental/mood disorders such as schizophrenia, bipolar disorder, and depression. The tablets are available in doses of 5mg. The medication guide provided by the pharmacist should be given to each patient. The NDC number provided is 65862-662-78. The rest of the text seems to be a mix of random letters, numbers, and symbols, so it is not useful information.*

FDA Label Image

Package Label-principal Display Panel (10 mg Blister Carton (10 x 10) Unit-dose Tablets)

These are tablets distributed by Aurobindo Pharma USA, Inc. Each tablet contains 10mg of Aripiprazole USP. Aripiprazole is usually prescribed medication, so a pharmacist should dispense it. The package insert contains instructions and dosage information. The tablets are in a closed container of 30 tablets and must be kept in a controlled room temperature. There is a code TSDRUGSI222009 and a coding area that is not to be printed.*

FDA Label Image

Package Label-principal Display Panel (15 mg (30 Tablets Bottle))

Aripiprazole Tablets USP with NDC code 65862-663-78. This medication guide is for pharmacists to dispense the medication guide separately to each patient. The box contains 100 (10 x 10) unit-dose tablets with each tablet containing Arpiprazoe USP 10g. There is additional text that is unreadable.*

FDA Label Image

Package Label-principal Display Panel (15 mg Blister Carton (10 x 10) Unit-dose Tablets)

This is a description of a medication called Aripiprazole. It comes in tablet form with a strength of 15 mg. The medication guide is included separately for each patient. The manufacturer is AP AUROBINDO, and there are 30 tablets per container. The medication should be stored at a controlled room temperature and in tightly closed containers. The usual dosage and other information can be found in the accompanying package insert. The medication is distributed by Aurobindo Pharma USA, Inc.*

FDA Label Image

Package Label-principal Display Panel (20 mg (30 Tablets Bottle))

Aripiprazole Tablets USP 15 mg is a prescription medication. Each pack contains 100 unit-dose tablets. Before dispensing the medication, pharmacists should provide the patient with the Medication Guide. Otherwise, no further information about the medication or its usage is available in the text.*

FDA Label Image

Package Label-principal Display Panel (20 mg Blister Carton (10 x 10) Unit-dose Tablets)

Each tablet contains 20 mg of Avipiprazole USP and is distributed by Aurobindo Pharma USA, Inc. The tablets are packaged with a package insert containing indications and dosage information. The National Drug Code (NDC) for this medication is 65862-665-30. The Drugs code for these tablets is TSDRUGS2212000. It is recommended to store these tablets at a temperature of 20° to 25° Celsius (68° to 77°F) in tightly closed containers. The pharmacist should distribute the medication with the patient medication guide. The text in the Over Printing Zone and Coding Area is not available.*

FDA Label Image

Package Label-principal Display Panel (30 mg (30 Tablets Bottle))

This is a description of Aripiprazole Tablets USP containing NDC code 65862-665-78. It includes specific instructions for pharmacists to dispense the medication guide to each patient. The package has 100 unit-dose tablets, 10 in each strip. The details of the drug's use and quantity are also present.*

FDA Label Image

Package Label-principal Display Panel (30 mg Blister Carton (10 x 10) Unit-dose Tablets)

FDA Label Image

Aripiprazole Fig19

This is a medication package for Aripiprazole Tablets USP manufactured by Aurobindo. The package contains 100 unit-dose tablets with 10 tablets in each blister. The tablets are only available with a prescription and the pharmacist should dispense the medication guide to each patient separately. The package also includes the National Drug Code (NDC) 65862-666-78.*

FDA Label Image

Figure 2: The Effects Of Other Drugs On Dehydro-aripiprazole Pharmacokinetics (Aripiprazole Fig2)

This is a table (Figure 2) showing the effects of different drugs on the pharmacokinetics of Aripiprazole. The table lists Dehydro-Aripiprazole Fold Change and 90% CI values for drugs that inhibit or induce certain enzymes responsible for metabolizing Aripiprazole, as well as for drugs that affect gastric acid or act as other inhibitors. The values listed in the table represent the change relative to the reference value (without interacting drug).*

FDA Label Image

Figure3: The Effects Of Aripiprazole On Pharmacokinetics Of Other Drugs (Aripiprazole Fig3)

The text provides a figure labeled as "Figure 3" that shows the effects of aripiprazole on the pharmacokinetics of several drugs, including extropmethorphan, swartarin, revartarin, omeprazole, lamotrigine, valproate, lorazepam, yontane, and O-desmethyivenlafaxine. The figure includes fold changes and 90% confidence intervals for the drugs. No further information is available.*

FDA Label Image

Figure4: Effects Of Intrinsic Factors On Aripiprazole Pharmacokinetics (Aripiprazole Fig4)

The text is describing different parameters to study the effects and changes of a drug on special populations. It includes information on PK AdpprzcleFad change, gender, age, hepatic impairment, and renal impairment. The text also provides numerical values for each parameter but is incomplete and difficult to interpret without further context.*

FDA Label Image

Figure 5: Effects Of Intrinsic Factors On Dehydro-aripiprazole Pharmacokinetics (Aripiprazole Fig5)

This appears to be a figure from a research article or report. It shows the effects of various intrinsic factors, such as gender, age, hepatic impairment, and renal impairment, on the pharmacokinetics of Dehydro-Aripiprazole. The figure includes a plot showing the change and 90% confidence intervals in Cmax (peak concentration) of Dehydro-Aripiprazole relative to a reference value, as well as a table listing the different factors and their respective categories (e.g. normal vs impaired). There is not enough context to determine the specific conclusions or implications of the data presented.*

FDA Label Image

Figure 6: Kaplan-meier Estimation Of Cumulative Proportion Of Patients With Relapse (schizophrenia Study 5) (Aripiprazole Fig6)

FDA Label Image

Package Label-principal Display Panel (2 mg (30 Tablets Bottle))

This is a chart that displays the least-squares mean change in YGTSS (Yale Global Tic Severity Scale) total TIC (Tourette's Syndrome) score from baseline, between ARIPIPRAZOLE LOW dose and ARIPIPRAZOLE HIGH dose over a period of 4 weeks of treatment with placebo included for comparison purposes. The values range from 0 to -5.*

FDA Label Image

Package Label-principal Display Panel (2 mg Blister Carton (10 x 10) Unit-dose Tablets)

FDA Label Image

Package Label-principal Display Panel (5 mg (30 Tablets Bottle))

This is a description of a medication named Aripiprazole Tablets USP. The medication comes in a package that contains 100 unit-dose tablets. Each tablet contains 2 mg of Aripiprazole USP. A pharmacist should dispense the medication with a separate medication guide provided to each patient. There is also a barcode on the package.*

FDA Label Image

Aripiprazole Structure (Aripiprazole Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.